Cardiogenic shock complicating acute coronary syndromes

Lancet

Volumn 356, Issue 9231, 2000, Pages 749-756

  Hasdai, David ^a   Topol, Eric J ^b   Califf, Robert M ^c   Berger, Peter B ^d   Holmes Jr , David R ^d  

^a RABIN MEDICAL CENTER   (Israel)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; CARNITINE; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ALGORITHM; CARDIOGENIC SHOCK; COUNTERPULSATION; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEART INFARCTION; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034718401     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02640-4     Document Type: Review

References (48)

1. Recent trends in hospital mortality of acute myocardial infarction - The Worcester Heart Attack Study: Have improvements been realized for all age groups?
2. Cardiogenic shock after acute myocardial infarction -incidence and mortality from a community wide perspective 1975-1988
3. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience
4. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation
5. Clinical features of sudden obstruction of the coronary arteries
6. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase: Results from GUSTO III
7. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation
8. Temporal trends in cardiogenic shock complicating acute myocardial infarction
9. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: Report of the SHOCK trial registry
10. Acute myocardial infarction
11. Acute right ventricular dilatation in response to ischemia significantly impairs left ventricular systolic performance
12. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction
13. Cardiogenic shock complicating myocardial infarction
14. Prognosis and management of anterolateral myocardial infarction in patients with severe left main disease and cardiogenic shock: The left main shock syndrome
15. Pathophysiology of cardiogenic shock: Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations
16. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
17. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction
18. Differences in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: Results from the GUSTO trial
19. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators
20. Cardiogenic shock complicating acute myocardial infarction: Predictors of mortality
21. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era
22. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
23. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)
24. Reteplase: A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction
25. Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction
26. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator
27. Intraaortic ballon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent
28. Use of intra-aortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the GUSTO-I Study
29. Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital
30. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock
31. Current spectrum of cardiogenic shock and effect of early revascularization on mortality
32. Early and 1-year survival rates in acute myocardial infarction complicated by cardiogenic shock: A retrospective study comparing coronary angioplasty with medical treatment
33. Usefulness of coronary stenting for cardiogenic shock
34. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial: An observational study
35. One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: Results from the GUSTO-I trial
36. Clinical and hemodynamic results of intraaortic balloon pumping and surgery for cardiogenic shock
37. Clinical and hemodynamic results of intra-aortic balloon counterpulsation and surgery for cardiogenic shock
38. Intraaortlc balloon counterpulsation with and without reperfusion of myocardial infarction shock
39. Cardiogenic shock following acute myocardial infarction: Late functional results after emergency cardiac surgery
40. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction: The (Swiss) Multicenter trial of Angioplasty for Shock - (S)MASH
41. An international randomized trial of 1138 patients comparing primary coronary angioplasty versus tissue plasminogen activator for acute myocardial infarction
42. Early revascularization in acute myocardial infarction complicated by cardiogenic shock
43. Effects of early revascularization for cardiogenic shock on 1 year mortality: The SHOCK trial results
44. Elderly patients at highest risk with acute myocardial infarction are more frequently transferred from community hospitals to tertiary centers: Reality or myth?
45. Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines
46. Insulin and glucose in treatment of cardiogenic shock
47. L-carnitine in cardiogenic shock therapy: Pharmacodynamic aspects and clinical data
48. Is adenosine 5-triphosphate derangement or free-radical-mediated injury the major cause of ventricular dysfunction during reperfusion? Role of adenine nucleoside transport in myocardial reperfusion injury